1. Irina Ishak appointed General Counsel, effective December 8, 2025. 2. Ishak brings extensive legal expertise in life sciences to Tonix. 3. Tonix recently launched TONMYA™, the first new fibromyalgia treatment in 15 years. 4. Company's pipeline includes CNS disorders and other critical therapeutic areas. 5. Ishak aims to support Tonix's next growth phase and product commercialization.
FAQ
Why Bullish?
The appointment of a seasoned attorney may strengthen regulatory and compliance frameworks, supporting product launches and partnerships, which is crucial for the growth phase of the company. Historical examples show that strong leadership in legal positions often positively influences stock performance.
How important is it?
The appointment of a new General Counsel at Tonix Pharmaceuticals indicates strategic prioritization in legal compliance and governance, primarily as the company scales operations with new products like TONMYA. The relevance is heightened due to the growth trajectory associated with the firm’s recent FDA approvals and advancements.
Why Long Term?
Ishak's role is pivotal for navigating Tonix through regulatory landscapes, potentially leading to successful product commercialization and pipeline advancement. Such impacts generally materialize over a longer time frame as products progress through clinical development and market acceptance.
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
Chatham, N.J., December 9, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has announced the appointment of Irina Ishak as General Counsel, effective December 8, 2025. In her new role, Ms. Ishak will oversee Tonix's legal, corporate governance, and compliance initiatives, playing a pivotal role in the company's operations as it advances its commercial-stage biotechnology portfolio.
Leadership Transition and Expertise
President and CEO of Tonix, Seth Lederman, M.D., praised Ms. Ishak's qualifications, stating, “Irina is a highly accomplished corporate and commercial attorney whose experience spans public and private life sciences companies, as well as advising life sciences investors.” He added that her expertise in complex transactions and public company governance is expected to be an invaluable asset as Tonix works to commercialize its marketed products and execute its long-term strategy.
Background and Experience of Irina Ishak
Prior to joining Tonix, Ms. Ishak was Senior Counsel at Lowenstein Sandler LLP since 2013, advising Tonix since 2017 on various strategic transactions, corporate governance, and securities matters. Her previous roles include Senior Director, Legal and Assistant Corporate Secretary at Savient Pharmaceuticals, where she played a significant role in obtaining FDA approval for KRYSTEXXA®, a treatment for chronic gout.
Ms. Ishak earned her J.D. from New York University School of Law and holds a B.A., with highest honors, from Rutgers College in New Brunswick, N.J.
Strategic Focus and Vision
Expressing her enthusiasm, Ms. Ishak remarked, “I am honored to join Tonix as General Counsel at such a pivotal moment in the Company’s evolution.” She highlighted the recent launch of TONMYA™, the first FDA-approved treatment for fibromyalgia in over 15 years, as an exciting milestone for the firm. Ms. Ishak is committed to supporting the Company’s growth and maximization of its innovative therapies.
Tonix Pharmaceuticals Overview
Tonix Pharmaceuticals is a fully integrated biotechnology company with a diverse pipeline of development candidates. Its flagship product, TONMYA™, is a first-in-class, non-opioid analgesic specifically for fibromyalgia—a chronic pain condition affecting millions. Additionally, Tonix markets Zembrace® SymTouch® and Tosymra® for acute migraine treatment. The company's broader development portfolio targets central nervous system disorders, immunology, rare diseases, and infectious diseases.
- TNX-102 SL: In development for acute stress reaction and major depressive disorder.
- TNX-1500: A monoclonal antibody targeting CD40-ligand for organ transplant rejection prevention.
- TNX-2900: An intranasal treatment in development for Prader-Willi syndrome.
- TNX-801: A vaccine candidate for mpox and smallpox.
Forward-Looking Statements
This announcement may contain forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Outcomes may vary substantially based on market conditions, regulatory approvals, and competitive landscape. Investors are encouraged to review risk factors detailed in Tonix's Annual Report on Form 10-K filed with the SEC.
Contact Information
For investor inquiries, please contact:
- Jessica Morris, Tonix Pharmaceuticals, investor.relations@tonixpharma.com, (862) 799-8599
- Brian Korb, ASTR Partners, brian.korb@astrpartners.com, (917) 653-5122